![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Hercules Capital Inc is a specialty finance company engaged in providing senior secured loans to high-growth, venture capital-backed companies in a variety of technology, life sciences, and sustainable and renewable technology industries. It invests primarily in structured debt with warrants and, to... Hercules Capital Inc is a specialty finance company engaged in providing senior secured loans to high-growth, venture capital-backed companies in a variety of technology, life sciences, and sustainable and renewable technology industries. It invests primarily in structured debt with warrants and, to a lesser extent, in senior debt and equity investments. The company lends to and invests in portfolio companies in various technology-related industries including technology, drug discovery and development, biotechnology, life sciences, healthcare, and sustainable and renewable technology. Show more
Harness Raises $150 Million in New Financing PR Newswire SAN FRANCISCO, May 14, 2024 Investment from Silicon Valley Bank and Hercules Capital Will Further Accelerate Platform Innovation SAN...
Hercules Capital, Inc. (NYSE: HTGC) (“Hercules” or the “Company”), will conduct its 2024 Annual Meeting of Stockholders by virtual meeting on Thursday, June 20, 2024 at 9:00 a.m. (Pacific Time...
Non-dilutive funding will support planned US commercial launch and expansion of ensifentrine’s clinical activities Cash runway extended beyond 2026 LONDON and RALEIGH, N.C., May 09, 2024...
Hercules Capital, Inc. (NYSE: HTGC) (“Hercules” or the “Company”), the largest and leading specialty financing provider to innovative venture, growth and established stage companies backed by...
Record Q1 2024 Total Gross Debt and Equity Commitments of $956.0 Million, an Increase of 81.7% Year-over-Year Record Q1 2024 Total Gross Fundings of $605.2 Million, an Increase of 27.1...
The Total Cash Distribution of $0.48 per Share for the First Quarter 2024 is Comprised of a $0.40 per Share Base Distribution and an $0.08 per Share Supplemental Distribution Hercules Capital...
SynOx Therapeutics secures up to $35m debt financing with Hercules Capital to progress development and commercialisation of emactuzumab PR Newswire DUBLIN and OXFORD, England, April 30, 2024...
Two Decades of Fueling the Growth of the Innovation Economy Hercules Capital, Inc. (NYSE: HTGC) (“Hercules” or the “Company”), is celebrating its 20th year of originations activity by reaching...
Period † | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0.43 | 2.20966084275 | 19.46 | 19.86 | 19.35 | 675518 | 19.71345903 | CS |
4 | 0.35 | 1.7911975435 | 19.54 | 19.975 | 19.25 | 678913 | 19.69351671 | CS |
12 | 1.39 | 7.51351351351 | 18.5 | 20.01 | 17.84 | 843946 | 19.19400551 | CS |
26 | 3.43 | 20.8383961118 | 16.46 | 20.01 | 16.44 | 900279 | 18.41797756 | CS |
52 | 5.74 | 40.5653710247 | 14.15 | 20.01 | 14.11 | 952572 | 17.16171977 | CS |
156 | 2.49 | 14.3103448276 | 17.4 | 20.01 | 10.94 | 1079421 | 15.64349548 | CS |
260 | 7.09 | 55.390625 | 12.8 | 20.01 | 5.42 | 952320 | 14.6776052 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions